{"url":"https://newsforagent.com/news/2026-11-05/billiontoone-cto-tsao-share-sale","markdown_url":"https://newsforagent.com/news/2026-11-05/billiontoone-cto-tsao-share-sale.md","title":"BillionToOne CTO David Tsao Sells $2.18 Million in Shares","headline":"BillionToOne CTO David Tsao Sells 20,000 Shares and Exercises Options at $2.8","description":"BillionToOne CTO David Tsao sold 20,000 Class A shares on November 2, 2026, and exercised 20,000 options at $2.8.","section":"Business","published_at":"2026-11-05T02:36:28+00:00","modified_at":"2026-11-05T02:36:28+00:00","author":"News Desk","key_takeaways":["David Tsao sold 20,000 Class A common shares of BillionToOne on November 2, 2026.","Tsao exercised options for 20,000 Class A shares at $2.8 per share.","After the transactions, Tsao directly held 1,000 Class A shares and 516,667 stock options."],"companies":[{"name":"BillionToOne","is_primary":true,"profile_url":"https://akta.pro/company-profiles/000029h/billiontoone","website":"https://www.billiontoone.com"}],"source":{"publisher":"The future of trading","title":"Billiontoone director and Chief Technology Officer David Tsao reports $2.18 million common share sale","url":"https://capital.com/en-int/news/billiontoone-director-and-chief-technology-officer-david-tsao-reports-2-18"},"other_sources":[],"tags":["Business","BillionToOne"],"body_markdown":"BillionToOne Chief Technology Officer and director David Tsao sold 20,000 Class A common shares on November 2, 2026, a transaction valued at $2.18 million, [The future of trading](https://capital.com/en-int/news/billiontoone-director-and-chief-technology-officer-david-tsao-reports-2-18) reported. Tsao also exercised options for 20,000 Class A shares at $2.8 per share.\n\n## Tsao's Share Sale and Option Exercise\n\nTsao is a co-founder of [BillionToOne](https://akta.pro/company-profiles/000029h/billiontoone), a Menlo Park-based precision diagnostics company founded in 2016 that sells non-invasive prenatal tests under the UNITY brand and oncology liquid biopsies under the Northstar brand from a single blood draw. The company's tests reach OB/GYNs, maternal-fetal medicine specialists and oncologists in the United States and Japan.\n\nThe filing covers two steps: the sale of 20,000 Class A common shares and the exercise of options for the same number of shares at $2.8 per share. After both transactions, Tsao directly held 1,000 Class A common shares and 516,667 stock options.\n\nBillionToOne published the original content behind the brief via EDGAR, the U.S. Securities and Exchange Commission's filing system, on November 4, 2026.\n\n## BillionToOne's Revenue and Funding Record\n\nBillionToOne reported full-year 2025 revenue of $305.1 million, up from $152.6 million in 2024, according to akta.pro [company records](https://akta.pro/company-data). Fourth-quarter 2025 revenue of $96.1 million represented 113% year-over-year growth. The company raised its full-year 2026 revenue guidance to $450-460 million, representing 48-52% growth versus 2025, after earlier 2026 guidance of $415-430 million.\n\nThe same records list eight funding rounds, including a $130 million Series D in June 2024 led by Premji Invest and a $125 million Series C in March 2022 led by Adams Street Partners. Total funding stands at $425.9 million.\n\n## Earlier BillionToOne Product and Partnership Moves\n\nIn May 2026, BillionToOne launched Unity Confirm, a non-invasive circulating fetal cell-based confirmation test using its Fetal Cell Capture technology, which showed 100% concordance with invasive diagnostics across 16 samples in clinical validation, according to the company records.\n\nIn April 2026, BillionToOne signed an in-network agreement with UnitedHealthcare effective April 1, 2026, expanding patient access to its tests and improving test pricing for UnitedHealthcare-insured patients. In January 2026, the company integrated UNITY Complete, Northstar Select and Northstar Response into Epic's Aura diagnostics suite under an agreement signed in December 2025, enabling in-EHR test ordering and results delivery into MyChart.\n\n## What Comes Next for BillionToOne\n\nBillionToOne has guided full-year 2026 revenue to $450-460 million, representing 48-52% growth versus 2025. The company's Unity Confirm test, launched in May 2026, is available following clinical validation across 16 samples.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}